CG Oncology, Inc. Common stock
CGONCG Oncology, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. The company leverages its proprietary antibody discovery platform to identify and develop novel immuno-oncology drugs aimed at improving patient outcomes in various cancer types.
Company News
CG Oncology announced positive Phase 2 results from CORE-008 Cohort CX evaluating intravesical cretostimogene combined with gemcitabine in high-risk BCG-exposed and BCG-unresponsive bladder cancer patients. The trial demonstrated high complete response rates (85.7-92.3%), high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months, ...
The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developme...
CG Oncology announced that its Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The company is a late-stage clinical biopharmaceutical firm developing bladder-sparing therapeutics for bladder cancer patients, with recent data showing promising effic...
CG Oncology appointed Christina Rossi, an accomplished life sciences executive with 25 years of pharmaceutical experience, to its Board of Directors. Simultaneously, Simone Song resigned from the board, marking a leadership transition as the company prepares for potential FDA approval of its bladder cancer therapeutic.
CG Oncology initiated a rolling Biologics License Application for cretostimogene, a potential bladder cancer treatment, demonstrating promising 24-month complete response rates and completing enrollment in a Phase 3 clinical trial for non-muscle invasive bladder cancer.
